Insight
Pashtoon Kasi
Pashtoon Kasi/LinkedIn

Pashtoon Kasi: Hot Off the Press – KRAS Vaccine for Patients with RAS+ Cancers

Pashtoon Kasi, Medical Director at City of Hope, shared on LinkedIn:

“Hot off the press!

KRAS Vaccine for patients with RAS+ cancers.

Benefit → durable.

More to come with the randomized study!

Opens to doors to off the shelf vaccine for so many patients with KRAS/NRAS mutations.”

KRAS Vaccine

Title: Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results

Journal: Nature Medicine

Authors: Zev A. Wainberg, Colin D. Weekes, Muhammad Furqan, Pashtoon M. Kasi, Craig E. Devoe, Alexis D. Leal, Vincent Chung, James R. Perry, Thian Kheoh, Lisa K. McNeil, Esther Welkowsky, Peter C. DeMuth, Christopher M. Haqq, Shubham Pant, Eileen M. O’Reilly

Read the full article.

KRAS Vaccine

More posts featuring Pashtoon Kasi on OncoDaily.

Alexis D. Leal AMPLIFY-201 cancer Christopher M. Haqq City of Hope Colin D. Weekes colorectal cancer Craig E Devoe Eileen M. O'Reilly Esther Welkowsky James R. Perry KRAS Vaccine KRAS/NRAS mutations Lisa K. McNeil mKRAS-specific amphiphile vaccine Muhammad Furqan OncoDaily Oncology Pancreatic Cancer Pashtoon Kasi Pashtoon M. Kasi Peter C. DeMuth RAS+ Cancers Shubham Pant Thian Kheoh Vincent Chung Zev A. Wainberg